Model‐informed dose selection for an investigational human epidermal growth factor receptor 2 antibody–drug conjugate FS‐1502 in patients with human epidermal growth factor receptor 2‐expressing advanced malignant solid tumours

Ähnliche Einträge

• Relaxin‐2 promotes osteoblastic differentiation mediated by epidermal growth factor and epidermal growth factor receptor signaling
  von: Lankai Yi, et al.
  Veröffentlicht: (2024)
• Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China
  von: Chunwei Xu, et al.
  Veröffentlicht: (2024)
• Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single‐agent fibroblast growth factor receptor‐specific inhibitors in pancreatic cancer
  von: Qingxiang Lin, et al.
  Veröffentlicht: (2024)
• Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection
  von: Ida Neldemo, et al.
  Veröffentlicht: (2025)
• First‐in‐human assessment of safety and pharmacokinetics of EP9001A:an anti‐nerve growth factor antibody for chronic pain treatment
  von: Yue Cheng, et al.
  Veröffentlicht: (2025)